Regulatory press release24.05.2025 klo 13.40Lipidor announces today negative results from the company's Phase III clinical study of AKP02G2 for psoriasis
Press release19.05.2025 klo 09.30Lipidor announces database lock in its Phase III clinical study of the psoriasis candidate AKP02G2
Press release21.01.2025 klo 09.00Lipidor announces half of patients enrolled in ongoing Phase III study
Press release20.11.2024 klo 09.00Lipidor publishes CEO statement for the quarter: "Study results expected by the end of Q1 2025"
Press release24.09.2024 klo 19.30Lipidor announces first patient enrolled in Phase III study of AKP02G2 for topical treatment of psoriasis
Press release20.08.2024 klo 14.50Lipidor announces that clinical trial material for psoriasis candidate AKP02G2 has been released according to plan
Regulatory press release01.07.2024 klo 09.15Lipidor resolves on a directed issue of shares to underwriters in connection with the completion of the rights issue
Regulatory press release25.06.2024 klo 22.57Lipidor's rights issue and share capital reduction are registered – conversion of BTU into shares and warrants
Regulatory press release12.06.2024 klo 21.58Lipidor announces preliminary outcome in the rights issue
Regulatory press release07.06.2024 klo 09.30Last day of trading in unit rights in Lipidor's rights issue
Regulatory press release05.06.2024 klo 11.00Bulletin from the Annual General Meeting of Lipidor AB (publ)
Regulatory press release29.05.2024 klo 09.00Today the subscription period in Lipidor's rights issue begins